Where is the company located?

The company is located in Shijiazhuang, Hebei, China.

What is the lead time for peak seasons?

The peak season lead time is one month.

Sodium Chloride Injection Large Volume (IV) Infusion PP Bottles USP/Bp

Name: Sodium Chloride Injection Large Volume (IV) Infusion PP Bottles USP/Bp
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 2148401995

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.17-0.20

10,000 Pieces

Sample price:US$0.20/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Infusion

Model NO.

500ml

Suitable for

Adult

State

Liquid

Shape

Infusion

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Transport Package

Carton

Specification

500ml plastic bag

Trademark

SHIMEN

Origin

China

HS Code

3004909099

Production Capacity

1000000

Key features

USP/BP Compliance: Meets United States Pharmacopeia and British Pharmacopoeia standards for quality assurance.

Large Volume Infusion: Available in 500ml, 250ml, and 100ml soft plastic bottle packaging options.

Clinical Indications: Treats dehydration, coma, metabolic alkalosis, and used for wound washing and labor induction.

GMP Certified Manufacturing: Produced by Shijiazhuang No.4 Pharmaceutical Co., Ltd. with SFDA GMP approval.

High Production Capacity: Annual output exceeds 1200 million bottles with over 40 million soft plastic bottles.

Global Market Reach: Products exported to South America, Africa, Asia, and other international regions.

Established Manufacturer: Company founded in 1948 with over 3000 employees and USD 58 million capital.

Flexible Payment Terms: Accepts LC and T/T payment methods for international transactions.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤18hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.